SanBio Co (JP:4592) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
SanBio Co. has completed its second commercial production run of AKUUGO suspension for intracranial implantation, achieving expected yield results. The company anticipates starting shipments by the second quarter of the fiscal year ending January 2026, pending compliance with specification tests. This development is expected to have minimal impact on the current fiscal year’s financial performance.
For further insights into JP:4592 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue